<DOC>
	<DOCNO>NCT00880815</DOCNO>
	<brief_summary>The goal clinical research study learn bendamustine , give stem cell transplant chemotherapy ( fludarabine rituximab ) , help transplant stem cell start grow make new blood cell patient leukemia lymphoma . The safety combination also study .</brief_summary>
	<brief_title>Fludarabine , Bendamustine Rituximab Conditioning Patients With Lymphoid Malignancies</brief_title>
	<detailed_description>The Study Drugs : Rituximab design attach lymphoma cell , may cause die . Fludarabine design make cancer cell less able repair damage DNA . This may increase likelihood cell die . Bendamustine design damage destroy DNA ( genetic material ) cancer cell . Study Drug Administration Stem Cell Transplant : If find eligible take part study , assign dose level bendamustine base join study . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue 4 dose level , high tolerable dose bendamustine find . You begin receive study drug within 30 day screen visit . All study drug give central venous catheter ( CVC ) leave place entire time receive study drug . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . On Day -13 ( 13 day receive stem cell transplant ) 1 time week 4 week , receive rituximab 5-7 hour CVC . If T-cell lymphoma , receive rituximab . On Days -5 -3 , receive fludarabine bendamustine 1 hour day CVC . During time , also receive hydrocortisone tacrolimus CVC help prevent ease side effect ( chill , rash , and/or hive ) . On Day -2 , start receive tacrolimus CVC help prevent graft-versus-host disease . This change dose tacrolimus mouth , discharge hospital . You continue take tacrolimus mouth 6-8 month follow transplant . On Days -2 -1 , stem cell match unrelated donor , receive thymoglobulin . On Day 0 , receive donor blood stem cell CVC 30-45 minute . On Days 1 , 3 , 6 ( stem cell transplant ) , receive methotrexate 30 minute day CVC help prevent graft-versus-host-disease . Patients receive match unrelated donor also give methotrexate day 11 transplant . Beginning Day 7 , receive filgrastim ( G-CSF ) needle skin 1 time day white blood cell count recover . Study Visits : You must stay Houston area 100 day stem cell transplant . You hospital 3-4 week receive stem cell transplant . During time , follow test procedure perform : - Blood ( 3 teaspoon ) collect routine test 1 time day . - When doctor think need , image scan ( one perform screen visit ) check status disease and/or possible infection . - When doctor think need , transfusion blood and/or platelet . - When doctor think need , bone marrow biopsy check status disease . Between Days 25 35 stem cell transplant , follow test procedure perform : - You CT scan check status disease . - Blood ( 6 teaspoon ) draw routine test . - You bone marrow biopsy/aspirate check status disease . - If doctor think need , PET scan check status disease . Long-Term Follow-Up : Every 3 month stem cell transplant first year every 6 month 3 year , follow test procedure perform : - You CT scan check status disease . - Blood ( 6 teaspoon ) draw routine test . - You bone marrow biopsy/aspirate check status disease . - If doctor think need , PET scan check status disease . Length Study : You study 3 year . You take study disease get bad experience intolerable side effect . End-of-Study Visit : After study , end-of-study visit . At visit , follow test procedure perform : - You CT scan check status disease . - Blood ( 6 teaspoon ) draw routine test . - You bone marrow biopsy/aspirate check status disease . - If doctor think need , PET scan check status disease . This investigational study . Rituximab fludarabine FDA approve commercially available treatment lymphoma . Fludarabine bendamustine FDA approve commercially available treatment chronic lymphocytic leukemia ( CLL ) . The use bendamustine combination study drug stem cell transplant treatment lymphoma leukemia investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . 18 70 year age . 2 . Patients cluster differentiation antigen 20 ( CD20 ) + CLL , marginal zone , mantle cell follicular lymphoma Tcell lymphoid malignancy eligible allogeneic transplantation . 3 . Patients relapse diffuse large Bcell lymphoma may include eligible autologous transplantation . 4 . A fullymatched sibling donor match unrelated donor . 5 . Left ventricular EF &gt; 40 % uncontrolled arrythmias symptomatic heart disease . 6 . Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) &gt; 40 % . 7 . Serum creatinine &lt; 1.6 mg/dL . Serum bilirubin &lt; 3X upper limit normal . 8 . Serum glutamate pyruvate transaminase ( SGPT ) &lt; 3X upper limit normal . 9 . Voluntary sign , write Institutional Review Board ( IRB ) approve informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 10 . Men woman reproductive potential must agree follow accepted birth control method duration study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . 1 . Patient active central nervous system ( CNS ) disease . 2 . Pregnant ( Positive Beta human chorionic gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization ) currently breastfeed . Pregnancy test require postmenopausal surgically sterilize woman . 3 . Known infection HIV , HTLVI , Hepatitis B , Hepatitis C. 4 . Patients malignancy diagnose within 2 year prior Study Day13 ( except skin squamous basal cell carcinoma ) . 5 . Active uncontrolled bacterial , viral fungal infection . 6 . History Stroke within 6 month . 7 . Myocardial infarction within past 6 month prior Study Day 1 , New York Heart Association ( NYHA ) Class III IV heart failure arrythmias , unstable angina , uncontrolled congestive heart failure arrythmias , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . 8 . A prior allogeneic transplant . 9 . Serious medical psychiatric illness likely interfere participation clinical study . 10 . Patient receive investigational drug within 3 week enrollment . 11 . Hypersensitivity bendamustine . 12 . Prior known refractoriness bendamustine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoid Malignancies</keyword>
	<keyword>Non-myeloablative Allogeneic Conditioning</keyword>
	<keyword>Non-myeloablative Allogeneic Hematopoietic Transplantation</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>Bendamustine HCI</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
	<keyword>CEP-18083</keyword>
	<keyword>SDX-105</keyword>
	<keyword>Treanda</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>FBR</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>GVHD</keyword>
</DOC>